Muhammad Shaalan Beg

Author

The University of Texas Southwestern Medical Center ORCID

Also Known As

Ari Baron, Farhan Siddiqui, Leticia Khosama, M S Beg, M. Beg, M. S. Beg, M. Shaalan Beg, M.S. Beg, Mohammad Sojon Beg, Muhammad Atif Beg

292

Publications

6.7K

Citations

H-Index

114

Concepts

All Affiliations

The University of Texas Southwestern Medical Center Southwestern Medical Center The University of Texas MD Anderson Cancer Center University of Cincinnati

About

Muhammad Shaalan Beg is an author at The University of Texas Southwestern Medical Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	33	1.5K
2	Health Sciences	5	5	188
3	Arts	1	1	38
4	Engineering	1	1	25
5	Nursing	1	1	38

Muhammad Shaalan Beg

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours David S. Hong, Yoon‐Koo Kang, Mitesh J. Borad, British Journal of Cancer	2020	850
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline John D. Gordan, Erin B. Kennedy, Ghassan K. Abou‐Alfa, Journal of Clinical Oncology	2020	601
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma Davendra Sohal, Mai Duong, Syed A. Ahmad, JAMA Oncology	2021	288
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma B. Sangro, Stephen L. Chan, Robin Kate Kelley, Annals of Oncology	2024	254
Establishment of a Multidisciplinary Hepatocellular Carcinoma Clinic is Associated with Improved Clinical Outcome Adam C. Yopp, John C. Mansour, Muhammad Shaalan Beg, Annals of Surgical Oncology Improved Clinical OutcomeHepatologyHepatocellular CarcinomaMedicineHistopathology	2013	230
Surgical Outcome Results From SWOG S1505 Syed A. Ahmad, Mai Duong, Davendra Sohal, Annals of Surgery	2020	225
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study James J. Harding, Jia Fan, Do‐Youn Oh, The Lancet Oncology MedicineBiliary CancerPathologyPharmacotherapyCancer Treatment	2023	201
Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer Alexander Drilon, D. Ross Camidge, Sang‐We Kim, New England Journal of Medicine	2024	178
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, The Lancet HepatologyTransarterial ChemoembolisationMedicinePharmacologyPathology	2025	151
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors Xiumei Huang, Edward A. Motea, Zachary Moore, Cancer Cell Nqo1 Bioactivatable DrugTumor BiologyPolymer-drug ConjugateMedicinePharmacology	2016	127

Page 1